Brenner Tumor of Ovary

Search Trials
The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
Status:
Recruiting
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Ovarian Cancer
Intervention(s):
Exercise CounselingAerobic ExercisePhysiological SupportQuality-of-Life AssessmentQuestionnaire AdministrationBest Practice
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Status:
Active, not recruiting
Last Changed:
May 5, 2017
First Changed:
Jan 1, 1970
Disease(s):
Fallopian Tube Clear Cell Adenocarcinoma
Intervention(s):
Elesclomol SodiumPaclitaxel
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Status:
Withdrawn
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Fatigue
Intervention(s):
Acetyl-L-Carnitine HydrochloridePlaceboQuestionnaire AdministrationQuality-of-Life Assessment
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Status:
Completed
Last Changed:
Apr 6, 2018
First Changed:
Jan 1, 1970
Disease(s):
Fallopian Tube Clear Cell Adenocarcinoma
Intervention(s):
BortezomibCarboplatinLaboratory Biomarker AnalysisPharmacological Study
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status:
Active, not recruiting
Last Changed:
Mar 1, 2019
First Changed:
Jan 1, 1970
Disease(s):
Fallopian Tube Endometrioid Adenocarcinoma
Intervention(s):
BevacizumabCarboplatinComputed TomographyPaclitaxelTherapeutic Conventional Surgery

Connect. Empower. Inspire.